Rhenman & Partners Asset Management AB Sells 32,500 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Rhenman & Partners Asset Management AB lowered its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 18.0% during the 4th quarter, Holdings Channel reports. The fund owned 147,600 shares of the company’s stock after selling 32,500 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Structure Therapeutics were worth $10,266,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GPCR. State of Wyoming bought a new position in Structure Therapeutics in the second quarter worth approximately $28,000. EverSource Wealth Advisors LLC boosted its holdings in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. CWM LLC boosted its holdings in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Structure Therapeutics in the second quarter worth approximately $129,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 0.9%

GPCR stock opened at $42.93 on Friday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The stock’s 50 day moving average is $43.64 and its 200-day moving average is $57.18. The firm has a market capitalization of $3.05 billion, a PE ratio of -49.34 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on GPCR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. HC Wainwright cut their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Finally, Citizens Jmp dropped their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.